New CSF Biomarkers for Alzheimer's Disease

Last updated: March 5, 2024
Sponsor: Central Hospital, Nancy, France
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dementia

Multiple Sclerosis

Neurologic Disorders

Treatment

N/A

Clinical Study ID

NCT03621839
2012-PSS/COLL- LCR/ARMAND/MS
  • All Genders

Study Summary

Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Lumbar punction collected in usual practice in the context of dementia diagnosis

Exclusion

Exclusion Criteria:

  • Absence of consent

Study Design

Total Participants: 50000
Study Start date:
July 12, 2013
Estimated Completion Date:
December 31, 2050

Connect with a study center

  • CHRU De Nancy

    Nancy, Grand Est 54500
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.